{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72","upperLimit":"97","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)\n\ndactinomycin: Given IV\n\ncyclophosphamide: Given IV\n\nvincristine sulfate: Given IV\n\nradiation therapy: Undergo radiotherapy","id":"OG000","title":"Regimen I (Chemotherapy, Radiotherapy)"}],"paramType":"NUMBER","populationDescription":"All eligible patients among this subset of regimen 1 patients were included in this outcome measure restricted to regimen 1 patients (there were 36 patients determined ineligible). Patients found not to meet the eligibility requirements are by group policy not followed for adverse events or outcome measures.","reportingStatus":"POSTED","timeFrame":"From enrollment up to 5 years","title":"Percentage of Patients With Stage 1, Clinical Group IIB or C (Node Positive) or Stage 2 Failure Free at 5 Years Following Study Entry","type":"PRIMARY","unitOfMeasure":"Estimated percentage of participants"}